Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (3285)	9/30/2002 6:40:53 PM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Rob, you suggested: >>Hospital drugs should be part of asset divestiture and excluded from product revenue>> If that is indeed the fact the situation is not as bleak as it might look. But, while there is a reference in the press release to a loss of revenue due to the asset disposal program, I doubt that it refers to the hospital products. The hospital products represent such a large part of the turnover (60 mUSD in Q2) that if they were not included in the reported figures Elan would and should have pointed that out. (It is much better to have 40 mUSD of unspecified revenue losses than 100 mUSD). Ice